People with HIV and fatty liver disease who were on INSTI drugs had similar body measurements at the start of the study compared to those not on INSTIs.

Scientific Claim

In people with HIV and non-alcoholic fatty liver disease, baseline anthropometric measurements did not differ between those receiving integrase inhibitor therapy and those not receiving it.

Original Statement

“These individuals were largely similar at baseline to those on regimens without INSTIs.”

From study:1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

definitive

Can make definitive causal claims

Assessment Explanation

This is a factual description of baseline characteristics, so the claim is appropriately stated without causal language.

Evidence from Studies

Supporting (1)

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Randomized Controlled Trial

Human

Contradicting (0)

No contradicting evidence found

Source Study

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Score: 63

DOI: 10.1093/ofid/ofad500.1334

Similar Assertions

Before starting treatment, people with HIV and fatty liver disease who were taking integrase inhibitors had similar body measurements as those not taking them.

97%

Out of 61 people with HIV and fatty liver disease in the study, 39 were taking integrase inhibitors, and most of those (41% of all participants) were on dolutegravir.

81%

Out of 61 people with HIV and fatty liver in the study, 39 were on INSTI drugs, and most of those (41%) were taking dolutegravir.

79%

Researchers looked at data from a previous study where 61 people with HIV and fatty liver disease were given either tesamorelin or a placebo, then focused on those taking integrase inhibitor drugs.

77%

For people with HIV and fatty liver disease on integrase inhibitors, taking tesamorelin for a year likely reduced liver fat by almost 5%, while the placebo group saw almost no change.

74%